Loading market event…
Loading market event…
Worth noting Market event Thu, Nov 19 1 min read
Thermo Fisher Scientific (TMO), a supplier of laboratory equipment and supplies, expects growth to strengthen in 2027 as biotechnology spending improves and academic research activity stabilizes, Chairman and CEO Marc Casper said during a UBS CEO Call Series discussion.[1]
These customers reach suppliers' revenue through two channels: greater biotech research spending can generate instrument orders and repeat purchases of reagents and other supplies used in experiments, while steadier academic activity can make that customer base's demand more predictable. Management's assessment therefore improves the demand outlook for laboratory suppliers, with faster revenue growth still dependent on customers turning budgets into purchases.[1]
Rival suppliers serving biotech companies and academic labs could also win orders as research spending improves. Benefits depend on each supplier's customer and product mix; Thermo Fisher's outlook alone does not establish an industry-wide recovery.[1]